share_log

Medicines and Healthcare products Regulatory Agency Grants Marketing Authorization for Novartis' Radioligand Therapy Pluvicto (Lutetium (¹⁷⁷lu) Vipivotide Tetraxetan) in Advanced Prostate Cancer in Great Britain

Medicines and Healthcare products Regulatory Agency Grants Marketing Authorization for Novartis' Radioligand Therapy Pluvicto (Lutetium (¹⁷⁷lu) Vipivotide Tetraxetan) in Advanced Prostate Cancer in Great Britain

药品和保健品监管机构批准诺华公司的放射配基治疗Pluvicto(Lutetium(?⁷⁷lu)Vipivotie Tetxetan)在英国晚期前列腺癌中的营销授权
Benzinga Real-time News ·  2022/08/12 04:56

Medicines and Healthcare products Regulatory Agency Grants Marketing Authorization for Novartis' Radioligand Therapy Pluvicto (Lutetium (¹⁷⁷lu) Vipivotide Tetraxetan) in Advanced Prostate Cancer in Great Britain

药品和保健品监管机构批准诺华公司的放射配基治疗Pluvicto(Lutetium(?⁷⁷lu)Vipivotie Tetxetan)在英国晚期前列腺癌中的营销授权

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发